Telatinib - Bayer/Eddingpharm

Drug Profile

Telatinib - Bayer/Eddingpharm

Alternative Names: BAY-57-9352; Telatinib mesylate

Latest Information Update: 03 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer
  • Developer ACT Biotech; Eddingpharm
  • Class Antineoplastics; Furans; Pyridazines; Pyridines; Small molecules
  • Mechanism of Action Platelet-derived growth factor beta receptor antagonists; Proto oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gastric cancer
  • No development reported Colorectal cancer

Most Recent Events

  • 13 Jun 2017 Eddingpharm Oncology plans a phase I trial to evaluate the safety and pharmacokinetics of telatinib in patients with advanced Solid tumours, in China (NCT03175497)
  • 13 Mar 2017 OncBioMune Pharmaceuticals announces term sheet with EOC Pharma for development of telatinib in Mexico, Central America and Latin America for Gastric cancer
  • 04 Aug 2015 No recent reports on development identified - Phase-I for Colorectal cancer in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top